1. Cervical Cancer DR KHALID H. WALI SAIT (FRCSC)
1920 colposcopy
1930 was used in Europe
USA
ACCSP
SHORT FOCAL LENGTH CAN NOT DO BIOPSY
LONG FOCAL LENGTH NOT COMFORTABLE PERFORM BIOPSY
5 % UNSATSF COLPOSCOPY
DR KHALID H. WALI SAIT (FRCSC)
ASSOCIATE PROFESSOR OF GYNECOLOGICAL ONCOLOGY
King Abdulaziz University Hospital, Jeddah, Saudi Arabia

2. Worldwide cervical cancer rates are high, particularly in developing countries.
According to information published by WHO in 2003:1
Cervical cancer is the second most common cancer (after breast cancer) among women worldwide.
Approximately 80% of new cases are reported from developing countries.
Worldwide prevalence is estimated at 2,274,000 cases, with approximately 510,000 new cases reported each year. Canada, in contrast, had an estimated incidence of 14,845 cases in
Without screening programs (i.e., routine Pap smears), cervical cancer is detected too late and leads to death in almost all cases.1
References
World Health Organization. State of the art of new vaccines research and development: Initiative for vaccine research. Geneva, Switzerland: World Health Organization; 2003:1–74.
Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;(31):3-13.

3. Cancer in Women
World Wide Breast Colo-rectal Cervix and Uterus Lung Leukemia-Lymphoma Ovary
Saudi Breast Thyroid Leukemia–Lymphoma Colo-rectal Ovary Liver Cervix Uterus

4. Female Genital Tract Malignancy
World Wide Uterus Cervix Ovary Vulva Vagina F.Tube
Saudi Ovary Cervix Uterus Vulva Vagina F.Tube

5. Pathogenesis HPV are etiological agent for cancer cervix
HPV DNA can be found in 99.7 % of all cervical carcinoma
Type 16, 18, 45 and 31 most frequent.
Several epidemiological and molecular studies over two decays

6. HPV Nonenveloped double-stranded DNA virus1 >100 types identified2
~30–40 anogenital2,3
~15–20 oncogenic*,2,3 types, including 16, 18, 31, 33, 35, 39, 45, 51, 52, 584
HPV 16 (54%) and HPV 18 (13%) accounted for the majority of worldwide cervical cancers.5
Nononcogenic** types include: 6, 11, 40, 42, 43, 44, 544
HPV 6 and 11 are most often associated with external genital warts.3
Key Point
There are many different types of HPV; of the ~15–20 oncogenic types, HPV 16 and HPV 18 account for the majority of cervical cancers.
Background
Papillomaviruses such as HPV are nonenveloped, double-stranded DNA viruses.1 More than 100 HPV types have been detected,2 with >80 types sequenced and classified.3 Approximately 30–40 types of HPV are anogenital, of which ~15–20 types are oncogenic.2,3 In an international meta-analysis (n = 10,058 invasive cervical cancer cases from 85 studies), HPV Types 16 and 18 are oncogenic and account for about two thirds of all cervical cancers—the next 5 most prevalent types (31, 33, 45, 52, 58) account for an additional 18% of cases.4 Other oncogenic HPV types include 35, 39, 51, and 56.5 HPV Types 6 and 11 are nononcogenic and are associated with external genital warts.3
References
1. Howley PM. Papillomavirinae: The viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 3rd ed. Philadelphia, Pa: Lippincott-Raven; 1996:2045–2076.
2. Schiffman M, Castle PE. Human papillomavirus: Epidemiology and public health. Arch Pathol Lab Med. 2003;127:930–934.
3. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: Diagnosis, treatment, and prevention. Clin Infect Dis. 2002;35(suppl 2):S210–S224.
4. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis. Br J Cancer. 2003:89;101–105.
5. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348: 518–527.
*High risk; **low risk
1. Howley PM. In: Fields Virology. Philadelphia, Pa: Lippincott-Raven; 1996:2045– Schiffman M, Castle PE. Arch Pathol Lab Med. 2003;127:930– Wiley DJ, Douglas J, Beutner K, et al. Clin Infect Dis. 2002;35(suppl 2):S210–S Muñoz N, Bosch FX, de Sanjosé S, et al. N Engl J Med. 2003;348:518– Clifford GM, Smith JS, Aguado T, Franceschi S. Br J Cancer. 2003:89;101–105.

7. Infectious Virus Particle of HPV1,2
1/Baker/p. 1449/Figure 3; p. 1453/col 2/¶ 2
2/Chen/p. 563/col 2/¶ 2
Capsid proteins: L1 L2
Key Point
HPV is a nonenveloped, double-stranded DNA virus; its shell is composed of L1 (major) and L2 (minor) proteins.
Background
HPV is a nonenveloped, double-stranded DNA virus encapsulated with an icosahedral shell.1,2 The virion is made up of 2 late capsid proteins — major (L1) and minor (L2).1,3
The virus shell consists of 72 pentamers, with each pentamer consisting of 5 molecules of L1 that stud the surface of the particle, and 1 molecule of L2 that sits in the conical hollow in the center of the rosette that faces inward.2,4
Virus neutralizing antibodies made in response to natural infections recognize conformational epitopes of L1 on the outer surface of the intact virus particle.5
References
1. Shah KV. Papovaviruses. In: Rose NR, de Macario EC, Folds JD, Lane HC, Nakamura RM, eds. Manual of Clinical Laboratory Immunology. 5th ed. Washington, DC: ASM Press; 1997:655–660.
2. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. Structures of bovine and human papillomaviruses: Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J. 1991;60:1445–1456.
3. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA. 1992;89:12180–12184.
4. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000;5:557–567.
5. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24(Suppl 1):S16–S22.
1/Shah/p. 655/col 1/¶ 3
Viral DNA
2/Baker/p. 1448/col 1/¶ 2
3/Kirnbauer/p /col 1/¶ 3/p /col 2/¶ 1
Viral exterior
Viral interior
4/Chen/p. 563/col 2/¶ 2/p. 557/col 1/¶2
1. Baker TS, et al. Biophys J. 1991;60:1445–1456.
2. Chen XS, et al. Mol Cell. 2000;5:557–567.
5/Stanley/p. 5/col 1/¶ 1

8. Pathogenesis
P53

9. Spectrum of Changes in Cervical Squamous Epithelium Caused by HPV Infection1
Normal Cervix
HPV Infection /
CIN* 1
CIN 2 / CIN 3 /
Cervical Cancer
Key Point
Integration of HPV into the DNA of the infected host cell is commonly associated with high-risk oncogenic HPV types1 and is linked to the activity of E6 and E7 proteins.2
Background
HPV infects its host by penetrating through mucosal tears in the basal membrane.3 In benign HPV-associated skin lesions, the HPV virus maintains its genome as episomes at low copy numbers (10–200 copies/cell) in the basal cells of the epithelium separate from the host cell DNA. To maintain its viral DNA as an episome, viral E1 and E2 proteins are expressed. Failure to express E1 leads to the integration of the HPV genome into the host cell chromosome.3
Integration of HPV into the DNA of the infected host cell is commonly associated with high-risk oncogenic HPV types1 and is considered an important step in tumor progression.2 In malignant HPV-associated skin lesions, HPV DNA integration into the host cell’s chromosome regularly occurs through a break in the viral genome around the E1/E2 region. Integration-mediated disruption of E2 may trigger uncontrolled expression of E6 and E7, resulting in cellular transformation.2
The E6 protein associates with the tumor suppressor protein p53 and promotes proteolytic destruction of the protein. This leads to malignant transformation and loss of regulated cell growth. The E7 protein associates with the retinoblastoma protein (pRB), which inactivates the cell cycle restriction function of this protein.2
References
1. Gallo G, Bibbo M, Bagella L, et al. Study of viral integration of HPV-16 in young patients with LSIL. J Clin Pathol. 2003;56:532–536.
2. Syrjänen KJ, Syrjänen SM. Molecular biology of papillomaviruses. In: Papillomavirus Infections in Human Pathology. Chichester, United Kingdom: John Wiley & Sons, Inc.; 2000:11–51.
3. Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;32(suppl):S7–S15.
*CIN = cervical intraepithelial neoplasia
1. Adapted from Goodman A, Wilbur DC. N Engl J Med. 2003;349:1555–1564. Copyright © 2003 Massachusetts Medical Society. All rights reserved. Adapted with permission.

10. Invasive Cervical Cancer
Natural History of HPV Infection and Potential Progression to Cervical Cancer1
0–1 Year
0–5 Years
1–20 Years
Initial HPV Infection
Continuing Infection
CIN 2/3
Invasive Cervical Cancer
CIN 1
Key Point
Infection with HPV will typically clear, but some infections with high-risk HPV types may ultimately lead to cervical cancer via a number of intermediate steps.
Background
Following initial HPV infection, the course of progression to cervical cancer depends on the type of HPV. Low-risk HPV types (such as HPV 6 or 11) have a negligible risk of progressing but may persist.1 Overall, the majority of HPV infections spontaneously clear within the first 24 months.2 High-risk types (such as types HPV 16 and 18) are often associated with CIN 2 or higher lesions. The strong association of HPV 16 with CIN 2 or greater suggests that lesions caused by this infection evolve to CIN 2 without a prolonged period as CIN 1.1  
Approximately 57% of low-grade lesions (CIN 1) will regress, 32% will persist, and 11% will progress. The risk of developing invasive cancer is estimated to be 1% in patients with CIN 1. Approximately 43% of CIN 2 lesions will regress, 35% will persist, 22% will progress to CIN 3, and 5% will progress to invasive cancer. The likelihood of CIN 3 regressing is about 32%, persistence is <56%, and rate of progression to invasive cancer is >12%.3 In studies of women with HPV infection who developed CIN 2 or 3, the initial abnormal smear was interpreted as CIN 2 or 3 in two thirds of cases,1,4 indicating that most CIN 3 lesions do not evolve from CIN 1.1 In a large, prospective study, mean times of progression from mild, moderate, or severe dysplasia to development of carcinoma in situ (CIS) were 58, 38, and 12 months, respectively.5   
In general, CIN occurs at least a decade earlier than invasive cancer, supporting a concept of the temporal evolution of cervical cancer.3 Based on a Markov model that approximated age-specific incidence of cervical cancer and HPV infection-associated events, the peak prevalence of low-grade squamous intraepithelial lesions (LSIL) is at 28 years of age, at 42 years of age for HSIL, and at 48 years of age for cervical cancer.6
References
1. Pinto AP, Crum CP. Natural history of cervical neoplasia: Defining progression and its consequence. Clin Obstet Gynecol. 2000;43:352–362.
2. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423–428.
3. Ostor AG. Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol. 1993;12:186–192.
4. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272–1278.
5. Richart RM, Barron BA. A follow-up study of patients with cervical dysplasia. Am J Obstet Gynecol. 1969;105:386–393.
6. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:1158–1171.
Cleared HPV Infection
1. Pinto AP, Crum CP. Clin Obstet Gynecol. 2000;43:352–362.

11. HPV Clearance
In women years of age ~80% of HPV infections are transient
Gradual development of cell-mediated immune response presumed mechanism
In a study of 608 college women, 443 infected, 70% of new infections cleared within 1 year and 91% within 2 years
Mean duration of infection - 8 months
HPV 16 and 18 infections persist longer
Key Point
Several studies have confirmed that HPV 16 is more likely to persist than other HPV types.1
Background
Several studies have evaluated the duration of HPV infection. In the study by Ho and colleagues, 608 college women in the United States were followed (mean age, 20 years) for an average of 2.2 years.2 The investigators reported median durations of infections of 11 months (95% CI, 7–12 months) and 12 months (95% CI, 6–17 months) with HPV types and 18, respectively. In contrast, the median duration of HPV 6 infection was 6 months (95% CI, 6–7 months).2
In a study of 1610 Colombian women 15–85 years of age (median age, 32 years), the median duration of high-risk HPV infection was 15 months (95% CI, 13–17 months), whereas the median duration of low-risk HPV infection was 11 months (95% CI, 8–17 months). Duration of infection with HPV types 16 and 18 were 14 months (95% CI, 8–19 months) and 12 months (95% CI, 9–17 months), respectively.3
Among university students 17–42 years of age (mean, 23 years) in Canada, Richardson and colleagues reported a slightly longer median time to loss of HPV infection in individuals infected with high-risk HPV types (17 months; 95% CI, 15–19 months) compared with individuals infected with low-risk HPV types (15 months; 95% CI, 11–18 months). Duration of infection for HPV types 16, 18, and 6 were 19 months (95% CI, 11–28 months), 9 months (95% CI, 5–14 months), and 6 months (95% CI, 5–8 months), respectively.4
In a study of the duration of HPV infection in 1075 women 15–19 years of age (median, 18 years) in the United Kingdom, Woodman and colleagues reported median durations of detectability of 10 months (95% CI, 7–17) for HPV 16, 8 months (95% CI, 6–13) for HPV 18, and 9 months (95% CI, 6–13) for HPV type 6 or 11.5
References
1. Molano M, van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: A population-based, 5-year follow-up study. Am J Epidemiol. 2003;158:486–494.
2. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423–428.
3. Muñoz N, Méndez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190:2077–2087.
4. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev. 2003;12:485–490.
5. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet. 2001;357:1831–1836.

12. Cervical Cancer Prevention
Education About early symptom of cancer cervix
Avoid Risk Factors
Screening and Vaccine

13. Risk Co Factor: HIV HPV 16,18 SMOKING MULTIPPLE SEXUAL PARTNER ? BCP

14. Cancer Cervix
Has an easily identified pre-invasive disease and be diagnosed and treated before become an invasive disease
Screening Test

18. THIN PREP Liquid based cytology

19. Q7

20. Recommendations of ACS(2004)
The present guideline reflect the current understanding of underlying epidemiology of CIN and the introduction of new technology in screening

21. False negative ( 30%)
GOOD SCREENING ?

22. Ideal (not essential) Patient’s Conditions For Screening
No vagina douching for 48 hours
Avoided use of contraceptive creams or jellies for 48 hours
No intercourse for 24 hours
Not recommended during menstruation, mid cycle smear is optimum
Patient should be required to provide her LMP

24. Changes in Terminology
L SIL
HPV
CIN I
Mild Dysplasia
H SIL
CIN II
Moderate Dysplasia
CIN III
Severe Dysplasia
Carcinoma insitu

25. Management Of Pap Smear Result
Pap smear is simply a lab test it is the responsibility of the physician to interpret the result in the context of a given patient and her particular circumstances

26. 1920 colposcopy
1930 was used in Europe
USA
ACCSP
SHORT FOCAL LENGTH CAN NOT DO BIOPSY
LONG FOCAL LENGTH NOT COMFORTABLE PERFORM BIOPSY
5 % UNSATSF COLPOSCOPY

27. Objective Of Colposcopy
Exclude invasive disease
Select the most appropriate area for biopsy

28. Detailed Colposcopic Exam.
Original squamocolumnar junction
Present squamocolumnar junction
Transformation zone
Endocervical canal
IS COLPOSCOPY SATISFACTORY ?

30. a grape-like or "sea-anemone"

32. RCT

34. Cancer of the Cervix Clinical presentation
Abnormal vaginal bleeding
Postmenopausal Vaginal bleeding
Vaginal discharge
Pain
Asymptomatic

35. Invasive Disease

36. Cancer of the Cervix Histological types
Squamous cell ca
Adenocarcinoma
Other

37. Cancer of the Cervix Mode of spread
Direct
Lymphatic
Hematogenous

38. Cancer of the Cervix Investigations
EUA
Complete blood count
Liver function test
Renal function tests
CXR/IVP or CT
Cystoscopy
Sigmoidoscopy

39. Cancer of the Cervix FIGO Staging ( clinical )
I - Tumour confined to the cervix
II- Upper 2/3 vagina / parametrium.
III- Lower 1/3 vagina / pelvic side wall or hydronephrosis
IV- Adjacent organ / Distant metastasis

40. Cancer of Cervix Prognostic Factors

41. Cancer of the Cervix Treatment of patients
Radical Hysterectomy and lymphadnectomy
Radiation Therapy and chemotherapy

43. Pelvic Radiation EBR and Brachytherapy
Chemotherapy

44. What is: Radiotherapy

45. How Radiotherapy works ?

46. Follow up

47. RECURRENT CERVICAL CANCER
Treatment depends on:
Site of recurrence
Mode of primary therapy

48. Pelvic Exenteration:

49. Cancer of the Cervix stage/survival

50. Prophylactic Vaccine
Virus – neutralization antibodies to prevent infection
Generate antibodies in genital tract epithelium directed against the L1 and L2 capsid proteins

51. Commercial HPV Vaccines
GSK vaccine (Harper 2004) 16/18(100% efficacy)
Merck vaccine (villa 2005) 6/11/16/18 ( 88% efficacy (RCT PLACEBO)
0,1,6 months
16-23 y old

52. Gardasil: Quadrivalent HPV Vaccine
0.5 ml IM, day 0, month 2, and month 6
COST ~$130 each vaccine dose
Storage: 2-8oC, should not be frozen, protect from light. *NEED TO PRESERVE THE “COLD CHAIN”*
Contraindications: hypersensitivity to the active substances or components
Precautions:
May not be effective
Not for use in active warts, cervical cancer, CIN VIN, VAIN
Does not provide protection against none vaccine HPV types
Not recommended for use in pregnancy, Category B

53. Who? Women 9-26 Do not need to have pap smear before vaccination
Testing for HPV is not recommended prior to vaccination
Sexually active women can be vaccinated, may be less effective in women who have been previously exposed to HPV

54. Cervical Cancer DR KHALID H. WALI SAIT (FRCSC)
1920 colposcopy
1930 was used in Europe
USA
ACCSP
SHORT FOCAL LENGTH CAN NOT DO BIOPSY
LONG FOCAL LENGTH NOT COMFORTABLE PERFORM BIOPSY
5 % UNSATSF COLPOSCOPY
DR KHALID H. WALI SAIT (FRCSC)
ASSOCIATE PROFESSOR OF GYNECOLOGICAL ONCOLOGY
King Abdulaziz University Hospital, Jeddah, Saudi Arabia